公开(公告)号：US08481049B2

公开(公告)日：2013-07-09

申请号：US11915727

申请日：2006-05-18

Applicant: Krishna Murthy Ella ,  Srinivas Kannappa Vellimedu

Inventor： Krishna Murthy Ella ,  Srinivas Kannappa Vellimedu

IPC: A61K38/18 ,  C07K14/485

CPC classification number: A61K38/50 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/06 ,  A61K9/10 ,  A61K31/355 ,  A61K31/375 ,  A61K31/555 ,  A61K31/716 ,  A61K31/728 ,  A61K35/14 ,  A61K35/644 ,  A61K36/185 ,  A61K36/886 ,  A61K36/9066 ,  A61K38/1808 ,  A61K38/1858 ,  A61K38/193 ,  A61K45/06 ,  A61K2300/00

Abstract: A composition for treating a wound, wherein the composition can comprise therapeutically effective amount of an epidermal growth factor and a physiologically acceptable agent, wherein the physiologically acceptable agent comprises at least one of a stabilizer, a preservative, a thickening agent, carrier/diluent, and optionally pH regulating agent and humectant.

Abstract translation: 一种用于治疗伤口的组合物，其中所述组合物可包含治疗有效量的表皮生长因子和生理学上可接受的试剂，其中所述生理学上可接受的试剂包括稳定剂，防腐剂，增稠剂，载体/稀释剂， 和任选的pH调节剂和保湿剂。

公开(公告)号：US09642907B2

公开(公告)日：2017-05-09

申请号：US12227250

申请日：2007-05-11

Applicant: Krishna Murthy Ella ,  Victor Jerusha Augustus Harshavardhan Gutla ,  Krishna Mohan Vadrevu ,  Smita Suneel Singhania

Inventor： Krishna Murthy Ella ,  Victor Jerusha Augustus Harshavardhan Gutla ,  Krishna Mohan Vadrevu ,  Smita Suneel Singhania

IPC: A61K39/15 ,  A61K39/12 ,  C12N7/00 ,  A61K39/00

CPC classification number: A61K39/15 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/542 ,  A61K2039/545 ,  A61K2039/55505 ,  C12N7/00 ,  C12N2720/12334

Abstract: The present invention relates to a composition comprising a viral antigen, a first protein and a second protein. Optionally, the composition also comprises three different disaccharaides, or, optionally, the composition comprises a primary sugar and at least one, preferably two secondary sugars. The present invention also relates to the use of a viral antigen, a first protein and a second protein for the manufacture of a composition, preferably a vaccine. The present invention furthermore relates to a method of treatment or prevention of virus associates diseases in humans. Moreover, the present invention relates to a method of adapting a virus to a suitable cell-line. The invention is also useful for the production of virus suspensions suitable for making stable, live/inactivated, monovalent and/or polyvalent, liquid/lyophilized rotavirus vaccine compositions for oral and/or nasal or any other suitable route of administration in human.

公开(公告)号：US08968728B2

公开(公告)日：2015-03-03

申请号：US12300150

申请日：2007-05-11

Applicant: Krishna Murthy Ella ,  Kandaswamy Sumathy

Inventor： Krishna Murthy Ella ,  Kandaswamy Sumathy

IPC: A61K38/48 ,  C12N9/72 ,  C12N9/70 ,  C12P21/04 ,  C07H21/04 ,  C07K1/00 ,  C07K14/31

CPC classification number: C07K14/31 ,  C07K2319/035

Abstract: New thrombolytic protein molecules such as recombinant staphylokinase or streptokinase, urokinase, tissue plasminogen activator and the like, and suitable variants thereof, for targeting to brain tissue or any other tissue by either fusing to, or by synthesizing the candidate thrombolytic molecule(s) with a protein sequence comprising a strong amphipathic alpha helix containing protein transduction domain. Thrombolytic protein molecule(s) so engineered with the protein transduction domain is useful for enhanced uptake of such protein thrombolytic molecule(s) across the cell membranes and tissues including the blood brain barrier and find their use in the treatment of vascular thrombosis including cerebrovascular disorders caused by cerebral thrombosis or cerebral haemorrhage when used a as a therapeutic. The design and processes for cloning, expression, purification and protein transduction of such proteins across cell membranes.

Abstract translation: 新的血栓溶解蛋白分子例如重组葡激酶或链激酶，尿激酶，组织纤溶酶原激活剂等及其合适的变体，用于通过融合或通过合成候选溶栓分子与脑组织或任何其他组织靶向， 包含含有蛋白质转导结构域的强两亲性α螺旋的蛋白质序列。 用蛋白质转导结构域进行工程化的溶血蛋白分子可用于增强这些蛋白质溶解分子在细胞膜和组织（包括血脑屏障）中的摄取，并用于治疗血管性血栓形成，包括脑血管障碍 由脑血栓形成或脑出血引起的，当用作治疗剂时。 克隆，表达，纯化和蛋白质转导这些蛋白质跨细胞膜的设计和过程。

公开(公告)号：US08956812B2

公开(公告)日：2015-02-17

申请号：US10585030

申请日：2004-08-23

Applicant: Krishna Murthy Ella ,  Srinivas Kannappa Vellimedu

Inventor： Krishna Murthy Ella ,  Srinivas Kannappa Vellimedu

IPC: C12Q1/70 ,  C12N7/02 ,  A61K39/00 ,  A61K39/205 ,  A61K39/29 ,  A61K39/02 ,  G01N1/18 ,  C07K14/005 ,  C07K1/36

CPC classification number: C07K14/005 ,  C07K1/36 ,  C12N2730/10122 ,  C12N2760/20122 ,  C12N2770/32422 ,  Y10T436/25375

Abstract: A novel process for the purification of recombinant protein expressed as particle is herewith described. In this purification process, the protein is purified by hydrophobic interaction. The interaction of this protein step resulted in an increase in recovery and purity from 15%-80%. The protein further purified has its application in vaccines and pharmaceuticals.

Abstract translation: 本文描述了用于纯化表达为颗粒的重组蛋白的新方法。 在该纯化过程中，通过疏水相互作用来纯化蛋白质。 该蛋白质步骤的相互作用导致15％-80％的回收率和纯度增加。 进一步纯化的蛋白质可用于疫苗和药物。

公开(公告)号：US20100068227A1

公开(公告)日：2010-03-18

申请号：US12227250

申请日：2007-05-11

Applicant: Krishna Murthy Ella ,  Victor Jerusha Augustus Harshavardhan Gutla ,  Krishna Mohan Vadrevu ,  Smita Suneel Singhania

Inventor： Krishna Murthy Ella ,  Victor Jerusha Augustus Harshavardhan Gutla ,  Krishna Mohan Vadrevu ,  Smita Suneel Singhania

IPC: A61K39/15 ,  A61K39/12 ,  A61P31/12 ,  A61P37/04 ,  A61P31/14

CPC classification number: A61K39/15 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/542 ,  A61K2039/545 ,  A61K2039/55505 ,  C12N7/00 ,  C12N2720/12334

Abstract: The present invention relates to a composition comprising a viral antigen, a first protein and a second protein. Optionally, the composition also comprises three different disaccharaides, or, optionally, the composition comprises a primary sugar and at least one, preferably two secondary sugars. The present invention also relates to the use of a viral antigen, a first protein and a second protein for the manufacture of a composition, preferably a vaccine. The present invention furthermore relates to a method of treatment or prevention of virus associates diseases in humans. Moreover, the present invention relates to a method of adapting a virus to a suitable cell-line. The invention is also useful for the production of virus suspensions suitable for making stable, live/inactivated, monovalent and/or polyvalent, liquid/lyophilized rotavirus vaccine compositions for oral and/or nasal or any other suitable route of administration in human.

Abstract translation: 本发明涉及包含病毒抗原，第一蛋白质和第二蛋白质的组合物。 任选地，组合物还包含三种不同的糖苷，或者任选地，组合物包含初级糖和至少一种，优选两种二级糖。 本发明还涉及病毒抗原，第一蛋白质和第二蛋白质用于制备组合物，优选疫苗的用途。 本发明还涉及治疗或预防人类疾病病毒相关疾病的方法。 此外，本发明涉及使病毒适应于合适的细胞系的方法。 本发明还可用于生产适用于制备用于口服和/或鼻或其它合适的人类给药途径的稳定，活/灭活的单价和/或多价液体/冻干轮状病毒疫苗组合物的病毒悬浮液。